Publication | Closed Access

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

Esophageal CancerMedicineBiweekly PaclitaxelPathologyErcc1 ExpressionCell BiologyCancer TreatmentOncologyRadiation OncologyCancer ResearchMolecular OncologyCisplatin Chemotherapy